In this FirefighterNation.com article, learn about the PPE challenges women firefighters face in the fire service.

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients ...

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 ...

Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ETCompany ParticipantsJames E.

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

Merck reports positive results from the first two phase 3 CORALreef trials of enlicitide decanoate to treat adults with hyperlipidemia: Rahway, New Jersey Tuesday, June 10, 2025, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug ...

The physical toll of parenting and caregiving is resulting in a significant rise in orthopedic conditions among primary caregivers, according to specialists at Mercy Health in a news release.

Adding simvastatin to escitalopram did not improve depressive symptoms in patients with major depression and obesity. Add-on ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced positive topline results from the first ...